Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ANGPT4
REST API REST API
Homo sapiens
ANGPT4 is differentially expressed in 120 experiments: 57 organism parts: liver, bladder, ... (55 more);, 120 disease states: normal, choriocarcinoma, ... (118 more);, 41 cell types 106 cell lines 9 compound treatments and 56 other conditions.
Orthologs Angpt4 (Mus musculus)   ANGPT4 (Danio rerio)   B2Z4B2_BOVIN (Bos taurus)   ENSCING00000005465 (Ciona intestinalis)   Angpt4 (Rattus norvegicus)   ANGPT4 (Canis familiaris)   (Compare orthologs)
InterPro Term Fibrinogen_a/b/g_C
Gene Ontology Term extracellular space, negative regulation of apoptosis, extracellular region, receptor binding, blood coagulation, anti-apoptosis, signal transduction, negative regulation of blood vessel endothelial cell migration, leukocyte migration, negative regulation of angiogenesis, positive regulation of peptidyl-tyrosine phosphorylation, cellular response to hypoxia, receptor tyrosine kinase binding, positive regulation of endothelial cell migration, positive regulation of angiogenesis, positive regulation of blood vessel endothelial cell migration, transmembrane receptor protein tyrosine kinase activator activity
UniProt Accession Q9Y264, B4E3J9
Search EB-eye ENSG00000101280
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (14 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-22152, E-GEOD-19639, E-GEOD-2450, E-GEOD-19480, ... (17 experiments)

Factor Value U/D Experiments
T47-D
1
E-GEOD-3529
Malme3M
1
E-MTAB-37
NCIH810
1
E-MTAB-37
ib3-1
1
E-MTAB-62
CaOv3
1
E-MTAB-37
HES2
1
E-MTAB-62
100 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-TABM-40, E-GEOD-6053, ... (21 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
immortalised T lymphocytes
1
E-GEOD-13909
native fetal RPE
1
E-GEOD-18811
CD8+ effector memory T cell
1
E-TABM-40
B cell
2
1
E-GEOD-13987
fetal RPE
1
E-GEOD-18811
35 more value(s).


Disease state

studied in E-GEOD-5390, E-GEOD-3307, E-GEOD-19743, E-MEXP-2069, E-MEXP-2442, ... (20 experiments)

Factor Value U/D Experiments
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
breast epithelial carcinosarcoma
1
E-MTAB-62
mesothelioma
1
E-MTAB-62
septic arthiritis
1
E-MTAB-62
no inhalation injury
1
E-GEOD-19743
114 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (7 experiments)

Factor Value U/D Experiments
rapamycin
1
E-GEOD-5824
interferon-gamma + lipopolysaccharide
1
1
E-GEOD-5099
lipopolysaccharide
9
1
E-TABM-868
bacterial endotoxin
1
1
E-GEOD-3284
none
1
1
E-GEOD-5824, E-TABM-868
hydrogen peroxide
2
1
E-GEOD-5339
3 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-18995, E-GEOD-19293 ... (5 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-563

Genotype
studied in E-GEOD-22056, E-TABM-868

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653

Individual
studied in E-GEOD-3284, E-GEOD-1432, E-MEXP-1243, E-GEOD-19519, E-MEXP-455, ... (12 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-5820

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19246

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Stimulation
studied in E-GEOD-11886

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Vehicle
studied in E-GEOD-5258

Processing time: 0.592 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM